The incidence of distant- and regional-stage colorectal cancer (CRC) has been increasing in individuals aged 46-49 years, a cross-sectional study of stage-stratified CRC found.
The European Medicines Agency has recommended Fruzaqla, Truqap, and Eribulin Baxter for use in the treatment of specific colorectal and breast cancers.
The update included background on the relationship between GLP-1 receptor agonists and endoscopic procedures, followed by clinical strategies for patients taking these medications.
Several new multitarget stool-based screening tests on the horizon may improve early colorectal cancer detection, according to findings from recent analyses.